Differing response to antipsychotic therapy in schizophrenia: Pharmacogenomic aspects

Dialogues in Clinical Neuroscience

Volumn 6, Issue 1, 2004, Pages 71-77

  Ackenheil, Manfred ^a   Weber, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic; Nonresponse; Pharmacogenomics; Pharmacokinetics; Schizophrenia

Indexed keywords

ACYLTRANSFERASE; CLOZAPINE; CYTOCHROME P450; HALOPERIDOL; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT;

DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PSYCHOPHARMACOTHERAPY; PUBLIC HEALTH; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1842563106     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Stip E. Happy birthday neuroleptics! 50 years later: la folie du doute. Eur Psychiatry. 2002;17:115-119.
2. Bottlender R, Sato T, Jager M, et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res. 2003;62:37-44.
3. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 1988;24:62-67.
4. Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999;60(suppl 12):22-23.
5. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am. 2000;9:43-76.
6. Kroemer HK, Eichelbaum M. "It's the genes, stupid." Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 1995;56:2285-2298.
7. Usuki E, Pearce R, Parkinson A, Castagnol N Jr. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol. 1996;9:800-806.
8. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003;31:243-249.
9. Halliday GM, Pond SM, Cartwright H, McRitchie DA, Castagnoli N Jr, Van der Schyf CJ. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol. 1999;158:155-163.
10. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517-2524.
11. Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56:78-83.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
13. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13:481-494.
14. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993;6:602-608.
15. McRitchie DA, Cartwright H, Pond SM, et al. The midbrain dopaminergic cell groups in the baboon Papio ursinus. Brain Res Bull. 1998;47:611-623.
16. 3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet. 1996;67:63-70.
17. Arranz MJ, Kerwin RW. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann Med. 2000;32:128-133.
18. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615-1616.